Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana.
| Revenue (TTM) | $5.02B |
| Gross Profit (TTM) | $2.78B |
| EBITDA | $1.01B |
| Operating Margin | 8.63% |
| Return on Equity | -2.98% |
| Return on Assets | 1.56% |
| Revenue/Share (TTM) | $10.09 |
| Book Value | $13.17 |
| Price-to-Book | 1.80 |
| Price-to-Sales (TTM) | 2.56 |
| EV/Revenue | 3.032 |
| EV/EBITDA | 19.64 |
| Quarterly Earnings Growth (YoY) | 440.50% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $499.62M |
| Float | $495.40M |
| % Insiders | 1.21% |
| % Institutions | 115.09% |
Volatility is currently expanding
The headline numbers for Elanco Animal Health (ELAN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.19 per share a year ago.
Accelerated Price, Organic Constant Currency Revenue Growth, and Gross Margin Expansion; Raising Full Year Outlook and Innovation Target; Achieved 2.9x Net Leverage Ratio Milestone Third Quarter 2026 Financial Results: Revenue of $1.265 billion, an increase of 11% year-over-year; 9% organic constant currency growth Reported Net Income of $18 million, Adjusted Net Income of $136 million Adjusted EBITDA of $243 million; Adjusted EBITDA Margin of 19.5% Reported EPS of $0.04, Adjusted EPS of $0.27 Net leverage ratio of 2.9x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.275 billion Raising revenue guidance to $5.155 billion to $5.18 billion, or approximately 8% organic constant currency growth Raising Adjusted EBITDA guidance to $1.05 billion to $1.065 billion, a year-over-year increase of 17% at midpoint Raising Adjusted EPS guidance to $1.17 to $1.20, a year-over-year increase of 26% at midpoint Improving year-end net leverage ratio target to approximately 2.9x Adjusted EBITDA with accelerated capital allocation flexibility 2027 Early Outlook: Building on expectations for full year 2026 outperformance, with continued expectation for 2027 results in line with December 2025 Investor Day annual algorithm: mid-single digit organic constant currency revenue growth, high-single digit Adjusted EBITDA growth, and low-double digit Adjusted EPS growth INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2026, provided guidance for the fourth quarter of 2026, updated guidance for the full year 2026, and provided an early outlook for the full year 2027. "Third quarter results demonstrate Elanco is a consistent, reliable growth company, delivering our diverse portfolio of innovation along with accelerating cash flow," stated Jeff Simmons, President and CEO of Elanco.
Latest U.S. Survey of 2,000+ Consumers Shows 93% of Pet Owners Maintained or Increased Pet Spending in Past Three Months, Omnichannel Shift Redefines Purchasing INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), today released findings from its latest U.S. consumer research, demonstrating that pet owners continue to fiercely protect health spending for their pets, affirming expectations for enduring strength of the animal health sector. According to the national omnibus survey of 2,018 U.S. consumers, including 1,495 dog and cat owners, fielded in mid-October 2026, pet health and wellness remains an indispensable household priority even as families navigate cost-of-living pressures: Pet Health Remains a Protected Household Priority: Despite broader macro pressures, 93% of pet owners surveyed maintained or increased pet spending over the past three months.
One stock has soared more than sevenfold this year, another just lost a quarter of its value on leaked data, and a third carries the fate of millions of retirees. Friday's earnings could test each rally in very different ways.
INDIANAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the UBS Global Healthcare Conference on November 9, 2026. Bob VanHimbergen, executive vice president and CFO, and Bobby Modi, executive vice president U.S. Pet Health and Global Digital Transformation will participate in a fireside chat on Monday, November 9 at 1:15 p.m.
Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Jamie Preston as Executive Vice President and Chief People Officer, effective November 3rd. Preston's appointment follows an extensive and competitive search as part of the company's commitment to attract, develop and retain an engaged global workforce while embedding inclusion, well-being and purpose into daily operations.
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ELAN and any ticker you trade — then tracks every position and per-strategy win rate.
